Furthermore, Gu et al. [107] proposed that the curcumin analogue AI-44, by targeting cathepsin B and inhibiting NLRP3 inflammasome activation, is a novel drug candidate for the treatment of gouty arthritis. The gene discussed is NLRP3; the disease is gout.